Navigation Links
Beckman Coulter to Present at the Thomas Weisel Healthcare Conference 2008
Date:8/22/2008

ORANGE COUNTY, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical testing, announced today that Charlie Slacik, Beckman Coulter's senior vice president and chief financial officer, will present at the Thomas Weisel Healthcare Conference 2008 on Thursday, September 4, 2008 at 8:00 a.m. (ET).

(Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO)

The live webcast of Beckman Coulter's presentation can be accessed by visiting their website at http://www.beckmancoulter.com. To access the webcast select "go to IR" under Investor Relations and find the event listed under "What's Ahead." The webcast will be archived on the company's website for future on-demand replay through Tuesday, October 28, 2008.

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represent more than 78 percent of the company's 2007 revenue of $2.76 billion. For more information, visit http://www.beckmancoulter.com.

Contact: Cynthia Skoglund (714) 773-8213

Manager, Investor Relations


'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Beckman Coulter Announces Second Quarter 2008 Results
2. Beckman Coulter Announces Second Quarter 2008 Earnings to be Released on Friday, July 25, 2008, Before Market Opens
3. Upcoming Beckman Coulter Investor Events Second Half of 2008
4. Beckman Coulter to Present at Upcoming Healthcare Conferences
5. Beckman Coulter Announces First Quarter 2008 Results
6. Beckman Coulter Acquires Rights to Hepatitis C Virus
7. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
8. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
9. Beckman Coulter to Present at the 2008 Bear Stearns London Healthcare Conference
10. Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell
11. AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc. for Molecular Quality Control Standards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... India , January 24, 2017 According to ... Culture, Cell Expansion, Cell Counting, Cell Line Development, Flow Cytometry, Single-Use Bioprocessing, ... to 2021", published by MarketsandMarkets, the global market is expected to reach ... a CAGR of 12.4% from 2016 to 2021. ... ...
(Date:1/24/2017)... Calif. , Jan. 24, 2017  Asterias ... pioneering the field of regenerative medicine, today announced ... Phase 1/2a clinical trial that showed additional motor ... of 10 million AST-OPC1 cells in AIS-A patients ... "Recovery of upper extremity motor function is ...
(Date:1/24/2017)... ... January 24, 2017 , ... Nanomedical ... assays for fragment-based screening, will showcase its proprietary Field Effect Biosensing ... and Screening (SLAS) conference in Washington, D.C. from Feb. 6 to Feb. 8. ...
(Date:1/24/2017)... , ... January 23, 2017 , ... ... supports innovative science through unique partnerships, seeks outstanding early career nominees for the ... is critical to meeting the needs of a world in which one in ...
Breaking Biology Technology:
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/16/2016)... The global wearable medical device market, in terms of value, is ... billion in 2016, at a CAGR of 18.0% during the forecast ... Growth ... devices, launch of a growing number of smartphone-based healthcare apps compatible ... and increasing focus on physical fitness. Furthermore, growing ...
Breaking Biology News(10 mins):